Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787378 | 0.98 | CYP2C9 (0.97) | CYP2C9CYP1A2ADRA1AHRH1 | |
| SCHEMBL787213 | 0.97 | CYP2C9 (0.93) | CYP2C9CYP1A2ADRA1AHRH1 | |
| SCHEMBL787623 | 0.93 | CYP2C9 (0.88) | CYP2C9CYP1A2ADRA1AHRH1 | |
| SCHEMBL787521 | 0.90 | CYP2C9 (0.82) | CYP2C9CYP1A2ADRA1AHRH1 | |
| SCHEMBL804389 | 0.90 | CYP2C9 (0.82) | CYP2C9CYP1A2ADRA1AHRH1 | |
| SCHEMBL787273 | 0.90 | CYP2C9 (0.82) | CYP2C9CYP1A2ADRA1AHRH1 | |
| SCHEMBL804711 | 0.89 | CYP2C9 (0.81) | CYP2C9CYP1A2ADRA1AHRH1 | |
| SCHEMBL787896 | 0.89 | CYP2C9 (0.79) | CYP2C9CYP1A2ADRA1AHRH1 | |
| SCHEMBL787090 | 0.88 | CYP1A2 (0.79) | CYP2C9CYP1A2 | |
| SCHEMBL804282 | 0.87 | CYP1A2 (0.77) | CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | GRM2, GRM1, GRIN2C | CYP2C9 3909/4885CYP1A2 3286/4885ADRA1A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.